HHMI
AZN icon

Howard Hughes Medical Institute’s AstraZeneca AZN Stock Holding History

Howard Hughes Medical Institute’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,417
Closed -$151K – 159
2017
Q1 		$151K Sell
2,417
-1,781
-42% -$104K 0.03% 128
2016
Q4 		$229K Buy
+4,198
New +$238K 0.05% 118

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Howard Hughes Medical Institute's AZN Position: Q2 2017 in Review

Howard Hughes Medical Institute sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 2,417 shares — an estimated $151K sold.

Howard Hughes Medical Institute first reported a position in AZN in Q4 2016 and held it in 2 quarters. The position peaked at $229K in Q4 2016. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

  • Howard Hughes Medical Institute reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 2,417 AstraZeneca shares in Q2 2017, an estimated $151K.
  • Howard Hughes Medical Institute first reported a position in AstraZeneca in Q4 2016 and held it in 2 quarters.
  • Howard Hughes Medical Institute's AstraZeneca position peaked at $229K in Q4 2016.
  • 466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Howard Hughes Medical Institute's 13F filing for Q2 2017, filed 11 Aug 2017.